Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Fractalkine Treatment Alleviates Symptoms of Type II Diabetes

By BiotechDaily International staff writers
Posted on 23 Apr 2013
Treatment of mouse diabetes models and in vitro cultures of human pancreatic cells with the protein fractalkine alleviated symptoms of type II diabetes by increasing insulin secretion and improving glucose tolerance.

Fractalkine (also known as chemokine (C-X3-C motif) ligand 1) is produced as a long 373-amino acid protein with an extended mucin-like stalk and a chemokine domain on top. The mucin-like stalk permits it to bind to the surface of certain cells. Furthermore, a soluble (90-kDa) version of this chemokine has also been observed. Soluble fractalkine potently attracts T-cells and monocytes, while the cell-bound chemokine promotes strong adhesion of leukocytes to activated endothelial cells, where it is primarily expressed. Fractalkine elicits its adhesive and migratory functions by interacting with the chemokine receptor CX3CR1.

Investigators at the University of California, San Diego (USA) studied the role of fractalkine in type II diabetes using a mouse model that had been genetically engineered to lack the gene for production of the fractalkine receptor CX3CR1. They reported in the April 11, 2013, issue of the journal Cell that these knockout mice exhibited a marked defect in glucose and GLP1 (glucagon-like peptide-1)-stimulated insulin secretion, and this defect was also observed in vitro in isolated pancreatic islets from CX3CR1 knockout mice. Pancreatic islet cells from the knockout mice exhibited reduced expression of a set of genes necessary for the fully functional, differentiated beta cell state, whereas treatment of wild-type (WT) islets with fractalkine led to increased expression of these genes.

Expression of fractalkine in islets was decreased by aging, high-fat diet, and obesity. In vitro treatment of islets with fractalkine increased intracellular calcium ion levels and potentiated insulin secretion in both mouse and human islets.

"Our discovery of fractalkine's role in beta cells is novel and has never been talked about in prior literature," said senior author Dr. Jerrold M. Olefsky, professor of medicine at the University of California, San Diego. "Whether or not decreased fractalkine or impaired fractalkine signaling are causes of decreased beta cell function in diabetes is unknown. What we do know, without doubt, is that administration of fractalkine improves or restores insulin secretion in all of the mouse models we have examined, as well as in human islet cells. If successfully developed, this could be an important new complement to the therapeutic arsenal we use in type II diabetes. It is not likely to cure diabetes, but it would certainly do a good job at providing glycemic control."

Related Links:
University of California, San Diego



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This micrograph depicts the presence of aerobic Gram-negative Neisseria meningitidis diplococcal bacteria; magnification 1150x (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).

Infection by Meningitis Bacteria Depends on Dimerization State of Certain Host Cell Proteins

A team of molecular microbiologists has untangled the complex three-way interaction between the non-integrin laminin receptor (LAMR1), galectin-3 (Gal-2), and the pathogenic bacterium Neisseria meningitidis.... Read more

Biochemistry

view channel

Discovery of Pain Receptor on T-cells Could Help Treat Autoimmune Disorders

Researchers have discovered that T-cells are activated by a pain receptor. The new findings revealed that the receptor helps control intestinal inflammation in mice and that its activity can be adjusted, providing a potential new target for treating certain autoimmune disorders, such as Crohn’s disease and possibly multiple... Read more

Lab Technologies

view channel
Image: Yale West Campus is organized into research institutes and core facilities — all designed to promote collaboration and interdisciplinary dialogue (Photo courtesy of Yale University).

American and European Partners Establish a Microscopy Center of Excellence

A prominent American university has announced a partnership agreement with a major European producer of microscopes and imaging tools that will establish a center for the use of cutting-edge imaging technologies... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.